Evidence map›Paper›PMID 32397113›Full record

ArticleInternational journal of molecular sciences2020

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.

Leylah M Drusbosky, Christopher R Cogle

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Cell-type Specific Alteration ofbioRxiv : the preprint server for biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Leylah M DrusboskyDivision of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Christopher R CogleDivision of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0001-5422-6863
University of Florida · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Celgene P0091329Leukemia and Lymphoma Society 2400-13NIH HHS UL1TR001427
6 · The paper itself

Abstract

Whereas lenalidomide is an effective therapy for del(5q) MDS patients, a minority of non-del(5q) MDS patients achieve hematologic improvement with lenalidomide. We used computational biology modeling and digital drug simulation to examine genomic data from 56 non-del(5q) MDS patients treated with lenalidomide, and then matched treatment response with molecular pathways. The computer inferred genomic abnormalities associating with lenalidomide treatment response in non-del(5q) MDS to include trisomy 8, del(20q), or

Indexed as

Biomarkers, PharmacologicalChromosome DeletionComputer SimulationDioxygenasesDNA-Binding ProteinsDrug ResistanceHigh-Throughput Nucleotide SequencingHumansKaryotypeLenalidomideMyelodysplastic SyndromesMyeloid Cell Leukemia Sequence 1 ProteinPhosphoproteinsPresenilin-2Proto-Oncogene ProteinsRNA Splicing FactorsBiomarkers, PharmacologicalDioxygenasesDNA-Binding ProteinsLenalidomideMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 ProteinPhosphoproteinsPresenilin-2Proto-Oncogene ProteinsPSEN2 protein, humanRNA Splicing FactorsSF3B1 protein, humanTET2 protein, humanWnt3A ProteinWNT3A protein, humancomputational modelingmyelodysplastic syndromesrefractory diseaseresistance

Identifiers

PMID32397113
PMCPMC7246771
OpenAlexW3021234977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.